1. Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant
- Author
-
Ekaterina I Ryabova, Dmitry V. Shcheblyakov, Denis Y. Logunov, Andrey G Botikov, Alexandr L. Gintsburg, Irina A Alekseeva, Ekaterina I. Aksenova, Irina A Favorskaya, Olga L. Voronina, Artem A Derkaev, Natalia N. Ryzhova, Boris S. Naroditsky, M.S. Kunda, Anna V. Kovyrshina, Ilias B Esmagambetov, Daria V Voronina, Daria A. Egorova, Inna V. Dolzhikova, Anna A. Iliukhina, Anastasia I Korobkova, and Olga V. Zubkova
- Subjects
chemistry.chemical_classification ,biology ,Coronavirus disease 2019 (COVID-19) ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Virology ,Neutralization ,Virus ,chemistry ,biology.protein ,Potency ,Antibody ,Glycoprotein ,Beta (finance) - Abstract
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern.
- Published
- 2021